Bacillus coagulans for feed expression bacteriocin and application thereof

By isolating and breeding Bacillus coagulis BCH0 strains that efficiently express bacterial , preparing bacterial , and applying them to feed additives , the demand for antibiotic substitutes in the animal husbandry industry is solved , and the inhibition of key pathogens and the improvement of livestock and poultry growth performance is achieved , It has high biosecurity and wide application prospects.

CN119020204APending Publication Date: 2024-11-26CHINA AGRI UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411090481.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

In the search for effective alternatives to antibiotics in the livestock industry, the existing technology is difficult to provide solutions that are free of side effects, drug residues, no resistance, and are widely used in livestock and poultry farming.

Method used

Bacillus coagulis BCH0 strain that efficiently expresses bacterin was isolated and bacterized through ultraviolet mutagenesis. Bacterin was prepared and applied to feed additives. Bacterin preparations were produced by solid fermentation method to inhibit gram-positive bacteria and improve livestock and poultry. Growth performance and intestinal microbiota regulation.

Benefits of technology

It has achieved effective inhibition of Staphylococcus aureus, Listeria and Clostridium perfringens, improved the growth performance and feed conversion efficiency of broiler chickens, and has high biosafety and wide application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention discloses bacillus coagulans for feed expression bacteriocin and application of the bacillus coagulans. The bacillus coagulans BCH0 (preservation number is CGMCC (China General Microbiological Culture Collection Center) No.26478) is gram-positive bacteria, spores are formed at the end, and the bacillus coagulans BCH0 is obtained by breeding after a soil sample is subjected to anaerobic enrichment culture in improved bromcresol purple glucose broth at 55 DEG C. The strain can tolerate the high temperature of 80 DEG C, has good acid resistance, is sensitive to 28 antibiotics such as penicillin, tetracycline and polymyxin, and can be applied to the field of biological engineering. The bacillus coagulans and the bacteriocin of the bacillus coagulans are safe and effective when being used for feeding animals, the growth performance of the broiler chickens can be effectively improved when the broiler chickens are fed, and the feed conversion efficiency is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of microbiology and probiotics for feed, and in particular relates to a bacteriocin-expressing bacillus coagulans for feed and application thereof. Background Art

[0002] Since the ban on antibiotics in the livestock industry, finding effective alternatives to antibiotics has become an imminent issue for the livestock industry. Compared with other antibiotic alternatives, feed probiotics have the advantages of no side effects, no drug residues, no resistance, and no pollution. They are an ideal antibiotic alternative.

[0003] Bacillus coagulans ( Bacillus coagulans ) is a lactic acid bacillus, a lactic acid-producing Bacillus. It is currently the only Bacillus allowed to be used in food in my country, and is also a species of bacteria allowed to be used in livestock and poultry farming in my country's feed additive catalog. Bacillus coagulans has the characteristics of both lactic acid bacteria and Bacillus. It has the strong stress resistance of Bacillus while producing high lactic acid. It is a highly potential probiotic with the effects of treating diarrhea, regulating intestinal flora and promoting digestion. Bacillus coagulans have been widely used in food, medicine and other fields.

[0004] Bacteriocin is an antibacterial metabolite produced by bacteria. It is a type of polypeptide or precursor polypeptide with antibacterial activity. It has better antibacterial properties, targeting, variability and combinability, making it an effective alternative to antibiotics. Therefore, the microecological preparations prepared by isolating and screening Bacillus coagulans that efficiently express bacteriocin can be more widely used in animal husbandry, aquaculture, food and pharmaceutical industries, and have great development prospects. Summary of the invention

[0005] The purpose of the present invention is to provide a feed-use bacillus coagulans expressing bacteriocin and application thereof.

[0006] In order to achieve the purpose of the present invention, in a first aspect, the present invention provides a strain of Bacillus coagulans ( Bacillus coagulans ) BCH0, which is a strain of Bacillus coagulans isolated from the deep soil of a mango field in Hainan, China, and was obtained by ultraviolet mutagenesis and selection to obtain a strain that efficiently expresses bacteriocin. The strain BCH0 has been deposited in the General Microbiology Center of China Microbiological Culture Collection Administration, No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, Postal Code 100101, with a deposit number of CGMCC No.26478 and a deposit date of January 13, 2023.

[0007] In a second aspect, the present invention provides a bacterial agent containing the Bacillus coagulans.

[0008] In a third aspect, the present invention provides a feed additive or animal feed containing the Bacillus coagulans.

[0009] In a fourth aspect, the present invention provides a medicine or composition containing the Bacillus coagulans.

[0010] In a fifth aspect, the present invention provides bacteriocin produced by the Bacillus coagulans.

[0011] In a sixth aspect, the present invention provides a method for preparing the bacteriocin, comprising: fermenting and culturing the Bacillus coagulans, centrifuging the fermentation broth to obtain a supernatant, precipitating the supernatant with ammonium sulfate, and centrifuging after precipitation to obtain a crude bacteriocin.

[0012] Preferably, the fermentation culture uses MRS liquid medium.

[0013] In a seventh aspect, the present invention provides use of the Bacillus coagulans, the bacterial agent or the bacteriocin in the preparation of an antibacterial biological product.

[0014] The antibacterial targets are Gram-positive pathogens, including but not limited to Staphylococcus aureus ( Staphylococcus aureus ) Listeria monocytogenes ( Listeria monocytogenes ) and Clostridium perfringens ( Clostridium perfringens ).

[0015] In an eighth aspect, the present invention provides a solid-state fermentation method of the Bacillus coagulans, comprising the following steps: (1) Resuscitation and activation of strains: Bacillus coagulans is thawed in a frozen tube and inoculated onto a solid bromocresol purple broth agar plate and cultured until a single colony grows; (2) Preparation of primary seed solution: Select a single colony from the plate and inoculate it into a YPD liquid shake flask and culture it until OD 600 The range is 1.5~2.0, which is used as the first-level seed solution; (3) Preparation of secondary seed solution: Inoculate the primary seed solution into a YPD liquid fermenter at a volume ratio of 0.5% to 5%, culture at 30 to 50°C, control the dissolved oxygen range to 10% to 30%, and fill the solution at 30 to 100 L; the fermentation time is controlled to be 16 to 24 h; (4) Solid-state fermentation: The solid-state fermentation material was sterilized at 110°C-121°C for 10-20 min and then cooled as a solid-state fermentation medium. The secondary seed liquid was inoculated into the solid-state fermentation medium at a ratio of 10%-50% by mass and stirred evenly. The stirring and fermentation temperature of the solid-state fermentation were controlled and maintained at 30-50°C. The fermentation was carried out for 24-48 h to obtain a solid-state inoculum. After the solid-state fermentation inoculum was dried and crushed, the number of viable bacteria in the solid-state fermentation product reached 5.0×10 8 ~9.0×108 CFU / g.

[0016] The solid fermentation material comprises, by weight, 100-200 parts of bran, 30-50 parts of soybean meal powder, 10-30 parts of corn flour, 10-30 parts of maltodextrin, 5-10 parts of corn cob powder, 1-2 parts of potassium dihydrogen phosphate and 0.5-1 part of manganese sulfate monohydrate.

[0017] In a ninth aspect, the present invention provides the use of the Bacillus coagulans or the solid-state fermentation product prepared according to the method as a feed additive for improving the growth performance of livestock and poultry and improving the intestinal flora of animals.

[0018] In a specific embodiment of the present invention, the application of Bacillus coagulans BCHO in promoting the growth of AA broilers is verified by examples.

[0019] By means of the above technical solution, the present invention has at least the following advantages and beneficial effects: (I) The Bacillus coagulans BCH0 of the present invention is a Gram-positive bacterium with terminal spores. It is obtained by breeding after placing a soil sample in a modified bromocresol purple glucose anaerobic enrichment culture at 55°C. The strain can withstand a high temperature of 80°C and grow in an acidic environment of pH 2.0.

[0020] (ii) Bacillus coagulans BCH0 is sensitive to 28 antibiotics, including penicillin, tetracycline, erythromycin, gentamicin, polymyxin, vancomycin, cefradine, amikacin, ampicillin, chloramphenicol, cephalexin, carbenicillin, clindamycin, cefoperazone, ciprofloxacin, ceftriaxone, cefuroxime, cefazolin, doxycycline, furazolidone, kanamycin, midecamycin, minocycline, neomycin, norfloxacin, ofloxacin, oxacillin, and piperacillin, and has extremely high biosafety.

[0021] (III) The bacteriocin produced by Bacillus coagulans BCH0 can inhibit Gram-positive bacteria Staphylococcus aureus, Listeria monocytogenes and Clostridium perfringens.

[0022] (IV) Bacillus coagulans BCH0 and its bacteriocin are safe and effective for feeding animals. Feeding broilers can effectively improve the growth performance of broilers and increase feed conversion efficiency. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 It is a colony morphology diagram of Bacillus coagulans BCHO of the present invention.

[0024] Figure 2 It is a Gram staining microscopic examination picture of Bacillus coagulans BCHO of the present invention.

[0025] Figure 3The agarose gel electrophoresis diagram of the 16S rDNA fragment of Bacillus coagulans BCHO of the present invention. The left and right lanes are DNA molecular weight marker and 16S rDNA amplification product, respectively.

[0026] Figure 4 This is a phylogenetic tree diagram of Bacillus coagulans BCHO of the present invention.

[0027] Figure 5 This is a reaction diagram of Bacillus coagulans BCHO dissolving calcium carbonate in a preferred embodiment of the present invention.

[0028] Figure 6 This is a diagram showing the inhibitory effect of the bacteriocin of Bacillus coagulans BCHO on Listeria monocytogenes ATCC 19111 in a preferred embodiment of the present invention.

[0029] Figure 7 This is a diagram showing the inhibitory effect of the bacteriocin of Bacillus coagulans BCHO on Clostridium perfringens CVCC2027 in a preferred embodiment of the present invention.

[0030] Figure 8 This is a diagram showing the inhibitory effect of the bacteriocin of Bacillus coagulans BCHO on Staphylococcus aureus ATCC25923 in a preferred embodiment of the present invention.

[0031] Figure 9 This is a sensitivity analysis test of Bacillus coagulans BCHO to different antibiotics in a preferred embodiment of the present invention.

[0032] Figure 10 This is a diagram of the tissue morphology of different tissues and organs of mice after gavage with Bacillus coagulans BCHO in a preferred embodiment of the present invention.

[0033] Figure 11 1 is an analysis chart of the heat resistance and acid resistance of the Bacillus coagulans BCHO sample in a preferred embodiment of the present invention.

[0034] Figure 12 This is a statistical analysis diagram of the intestinal tissue morphology and villus height of AA broiler chickens after feeding Bacillus coagulans BCHO in a preferred embodiment of the present invention.

[0035] Figure 13 This is an analysis diagram of the alpha diversity and beta diversity of ileum intestinal microorganisms of AA broiler chickens after feeding Bacillus coagulans BCHO in a preferred embodiment of the present invention.

[0036] Figure 14 This is an analysis diagram of the ileum intestinal microbial composition of AA broiler chickens after feeding Bacillus coagulans BCHO in a preferred embodiment of the present invention. DETAILED DESCRIPTION

[0037] The present invention provides a feed Bacillus coagulans BCHO which efficiently expresses bacteriocin, has antibacterial ability, is heat-resistant and acid-resistant, and a screening method and a solid-state fermentation method and applications thereof, and evaluates the growth-promoting effect of the modified strain through safety evaluation and livestock and poultry breeding experiments.

[0038] The present invention adopts the following technical solution: In the present invention, Bacillus coagulans ( Bacillus coagulans ) was isolated from the deep soil of a mango field in Hainan. After ultraviolet mutagenesis and selection, a strain with high efficiency in expressing bacteriocin was obtained. The strain was named BCH0 and its preservation number is CGMCC No.26478.

[0039] The present invention also provides Bacillus coagulans ( Bacillus coagulans ) A screening method for BCHO, the screening method comprising the following steps; (1) Sample collection: Weigh 1 g of soil sample under sterile conditions, add 9 mL of sterile saline and sterilized glass grinding beads, and shake to mix to obtain a mixed suspension; (2) Strain enrichment: Use modified bromocresol purple glucose broth as the enrichment medium for enrichment culture. Inoculate the mixed suspension and culture to obtain the enriched bacterial liquid. Culture anaerobically at 55°C for 24-48 h. (3) Isolation and purification of bacterial strains: The enriched bacterial liquid was diluted in a gradient manner and spread on bromocresol purple glucose broth agar medium. It was cultured anaerobically in an incubator at 55°C for 24 to 48 h to obtain the colonies to be purified. After repeated streaking and isolation culture, pure colonies of Bacillus coagulans were obtained. After mutagenesis and selection, the strain BCH0 was finally obtained.

[0040] Furthermore, the present invention provides an improved bromocresol purple glucose broth, the ingredients of which are as follows: 10 g / L peptone, 3 g / L beef extract powder, 10 g / L glucose, 5 g / L sodium chloride, 0.04 g / L bromocresol purple and 0.2 g / L sodium azide.

[0041] The Bacillus coagulans of the present invention ( Bacillus coagulans ) The microbiological characteristics of BCH0 are: Gram-positive Bacillus, the colony size on the modified bromocresol purple glucose broth solid medium is 5-10 mm, yellow to dark yellow opaque round colonies, the colony surface is smooth, the center is slightly convex, and the colony edge is smooth. The bacteriocin protein extracted after fermentation of Bacillus coagulans can effectively inhibit Staphylococcus aureus, Listeria and Clostridium perfringens.

[0042] The present invention provides a Bacillus coagulans that efficiently expresses bacteriocin ( Bacillus coagulans ) A solid-state fermentation method of BCHO, comprising the following steps: (1) Bacterial strain resuscitation and activation: Bacillus coagulans (Bacillus coagulans ) BCH0 was thawed in the cryotube and inoculated on a solid bromocresol purple broth agar plate. It was cultured at 47°C for 12-24 h until a single colony grew. The typical characteristics of the colony were yellow colonies with smooth edges. A single colony was picked again and inoculated on a solid bromocresol purple broth agar plate.

[0043] (2) Preparation of primary seed solution: Select a single colony from the seed plate and inoculate it into a YPD liquid shake flask. Incubate it in a shaker at 47°C and 200 r / min for 12-24 h as the primary seed solution. 600 The range is 1.5~2.0.

[0044] (3) Preparation of secondary seed solution: Inoculate the primary seed solution in a YPD liquid fermenter at a ratio of 0.5% to 5%, culture at 30 to 50°C, control the dissolved oxygen range to 10% to 30%, and fill the solution in a volume of 30 to 100 L. The fermentation time is controlled to be 16 to 24 h.

[0045] (4) Solid-state fermentation: The solid-state fermentation material is sterilized at 110°C-121°C for 10-20 min and then cooled for use. The deep fermentation liquid is inoculated into the solid-state fermentation medium at a ratio of 10%-50% and stirred evenly. The stirring and fermentation temperature of the solid-state fermentation are controlled and maintained at 30-50°C. The fermentation is carried out for 24-48 h to obtain a solid bacterial agent. The number of live bacteria in the solid product obtained after drying and crushing the solid-state fermentation bacterial agent can reach 5.0×10 8 ~9.0×10 8 CFU / g.

[0046] Furthermore, the present invention provides a solid-state fermentation medium formula, the components of which are specifically the following by weight: 100-200 parts of bran, 30-50 parts of soybean meal powder, 10-30 parts of corn flour, 10-30 parts of maltodextrin, 5-10 parts of corn cob powder, 1-2 parts of potassium dihydrogen phosphate and 0.5-1 part of manganese sulfate monohydrate.

[0047] The present invention provides a method comprising a bacillus coagulans ( Bacillus coagulans )BCH0 feed additive. The number of viable bacteria in the feed additive BCH0 is 5.0×10 8 ~9.0×10 8 CFU / g.

[0048] The present invention includes the Bacillus coagulans ( Bacillus coagulans ) Application of BCH0 in inhibiting Staphylococcus aureus.

[0049] The present invention includes the Bacillus coagulans ( Bacillus coagulans ) Application of BCH0 in inhibiting Listeria monocytogenes.

[0050] The present invention includes the Bacillus coagulans (Bacillus coagulans ) Application of BCH0 in inhibiting Clostridium perfringens.

[0051] The present invention includes the Bacillus coagulans ( Bacillus coagulans ) BCH0 is sensitive to 28 antibiotics including penicillin, tetracycline, polymyxin, etc. and has high biosafety.

[0052] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and the raw materials used are all commercially available products.

[0053] Example 1 Bacillus coagulans ( Bacillus coagulans )Separation and breeding of BCH0

[0054] 1. Bacillus coagulans ( Bacillus coagulans ) Isolation and culture of BCH0

[0055] 1. Improved bromocresol purple glucose broth: peptone 10 g, beef extract powder 3 g, glucose 10 g, sodium chloride 5 g, bromocresol purple 0.04 g, sodium azide 0.2 g, water 1 L, adjust pH to 6.8-7.0, sterilize at 115℃ for 15 min.

[0056] 2. Improved bromocresol purple glucose broth agar: 10 g peptone, 3 g beef extract powder, 10 g glucose, 5 g sodium chloride, 15 g agar powder, 0.04 g bromocresol purple, 0.2 g sodium azide, 1 L water, adjust pH to 6.8-7.0, and sterilize at 115℃ for 15 min.

[0057] 3. Soil sample collection: Soil samples were collected from a mango field in Hainan. 1 g of the sample was placed in a 100 mL sterile conical flask, 9 mL of sterile saline was added, an appropriate amount of sterilized glass grinding beads was added, and the mixture was shaken to obtain a soil mixed suspension.

[0058] 4. Enrichment of target bacteria: Use modified bromocresol purple glucose broth as the enrichment medium for enrichment culture. After the soil mixed suspension is filtered through a 100 μm filter membrane, it is inoculated into modified bromocresol purple glucose broth and cultured anaerobically at 55°C for 24-48 hours to obtain the enrichment culture solution.

[0059] 5. Isolation and purification of bacterial strains: Use sterile saline to perform gradient dilution on the enriched bacterial liquid, spread it on bromocresol purple glucose broth agar medium after gradient dilution, and culture it anaerobically in an incubator at 55℃ for 24-48 h. After colonies grow, select light yellow to yellow round colonies with smooth edges, purify the colonies, and obtain pure colonies through repeated streaking and isolation culture, and store them by number.

[0060] 6. Identification of bacterial strains: Inoculate the selected pure strain colonies into 5 mL of modified bromocresol purple glucose broth medium and culture at 47°C in a shaking incubator for 24 h. Use a bacterial genomic DNA extraction kit to extract the genomic DNA of the strain according to the instructions. Use the 16S rRNA primers of the strain (the primers include 27F: AGAGTTTGATCMTGGCTCAG, 1492R: GGTTACCTTGTTACGACTT) to amplify the 16S rDNA fragment, send the PCR product to Shanghai Sangon Biotechnology Technology Service Co., Ltd. for sequencing, and then perform BLAST comparison (https: / / blast.ncbi.nlm.nih.gov / Blast.cgi). According to the comparison results, the sequence was identified as Bacillus coagulans ( Bacillus coagulans ) strains.

[0061] 7. Bacteria selection: The selected Bacillus coagulans ( Bacillus coagulans ) were inoculated into MRS broth medium and cultured in a shaking incubator at 47°C for 24-48 h. The Oxford cup method was used to evaluate the antibacterial activity of the selected Bacillus coagulans against Staphylococcus aureus ( Staphylococcus aureus ), Clostridium perfringens ( Clostridium perfringens ) and Listeria monocytogenes ( Listeria monocytogenes ) to select the strain with the strongest antibacterial ability. The strain mutagenesis was carried out by ultraviolet mutagenesis. A liquid suspension was prepared for the strain with the best antibacterial performance and diluted to a concentration of 1.0~5.0×10 8 CFU / mL, 20-30 mL was placed in a 10 cm sterile plate and treated with a 15 W ultraviolet lamp for 60-150 s. The lethality was controlled at 50%-80%. The induced bacterial liquid was spread on a modified bromocresol purple glucose broth agar plate and cultured at 47 °C in the dark for 24-48 h. The induced bacteria were selected for cultivation, and the strain with the strongest antibacterial activity was finally obtained, which was named BCH0.

[0062] 2. Bacillus coagulans ( Bacillus coagulans )Growth characteristics and physiological and biochemical characteristics of BCHO

[0063] 1. Colony morphology: Take Bacillus coagulans in the logarithmic growth phase ( Bacillus coagulans ) BCH0 bacterial solution was diluted to different multiples according to the 10-fold dilution method and coated on the modified bromocresol purple glucose broth agar plate. It was cultured at 47℃ for 18-36 h. The plates with colony counts between 30 and 200 were selected for observation and photographed. The colony morphology was as follows: Figure 1 As shown, the colony size of BCH0 on the modified bromocresol purple glucose broth agar plate is 2-4 mm, and it is a yellow opaque round colony with a smooth surface, a convex center, and a regular colony edge.

[0064] 2. Gram staining of BCH0 strain: Take the logarithmic growth phase of Bacillus coagulans ( Bacillus coagulans ) BCH0 bacterial solution, take 2~3 drops and apply them on a glass slide, fix the flame of the alcohol lamp, operate according to the Gram staining kit, and observe the stained samples under an oil microscope. The test results are as follows Figure 2 As shown, BCH0 is blue-purple rod-shaped, and Bacillus coagulans ( Bacillus coagulans ) BCH0 is a Gram-positive bacterium.

[0065] 3. Analysis of 16S rRNA sequence homology and construction of phylogenetic tree of BCH0 strain

[0066] The 16S rRNA of the BCH0 strain was identified according to the steps described in the strain identification method. The size of the 16S rDNA product of the BCH0 strain was about 1500 bp ( Figure 3 ), which meets the sequence requirements, and the sequencing result is shown in SEQ ID NO: 1. The phylogenetic tree was constructed by selecting 16S rRNA gene sequences with similar homology from GenBank, using MEGA11.0 software, and using the nearest neighbor method (Neighbor-joining) after sequence alignment. The test was performed by bootstrap method (Bootstrap), and repeated 2000 times. The phylogenetic tree of BCH0 is shown in Figure 4 As shown, the homology comparison results determined that the type of BCH0 strain was Bacillus coagulans ( Bacillus coagulans ), the similarity is 99.10%.

[0067] 4. Biochemical identification and lactic acid production performance analysis of BCHO strain

[0068] The biochemical identification of BCH0 was carried out according to the instructions of HBI biochemical identification strips. The two BCHO strains were inoculated with bacterial suspension and puncture inoculation for analysis and detection. The various biochemical reactions of the strains were tested, including VP, citrate, gelatin, 7% sodium chloride, pH 5.7, nitrate reduction, starch hydrolysis, propionate, D-xylose, L-arabinose and D-mannitol. The results are shown in Table 1. BCH0 meets the biochemical characteristics of Bacillus coagulans.

[0069] Table 1 HBI biochemical identification

[0070] The lactic acid production capacity of BCH0 is tested through calcium dissolution reaction. Calcium carbonate generates soluble calcium lactate under the action of lactic acid. The solid MRS culture medium is sterilized at 121 °C. Calcium carbonate is sterilized separately after adding water. When the temperature of MRS solid culture medium is cooled to 45-55 °C, calcium carbonate is added to the solid culture medium at a dosage of 0.5%. After sufficient mixing, the plate is quickly poured to avoid precipitation of calcium carbonate. The strain of BCH0 is streaked and inoculated in MRS solid culture medium with calcium carbonate added, cultured at 47 °C for 24-36 h, and the size of the calcium melting circle is observed. The results are as follows: Figure 5 As shown, BCHO has a good lactic acid production ability, which is consistent with the lactic acid production characteristics of Bacillus coagulans.

[0071] Example 2 Bacillus coagulans ( Bacillus coagulans )Extraction and antibacterial performance analysis of BCH0 bacteriocin

[0072] Take Bacillus coagulans in the logarithmic growth phase ( Bacillus coagulans ) BCH0 bacterial liquid was inoculated into MRS medium at a ratio of 1%, and cultured at 45-50°C for 24-72 h. The cultured bacterial liquid was centrifuged at 6000 rpm for 10 min to remove the bacteria. The supernatant was filtered through a filter membrane and the bacteriocin protein was precipitated in 75% saturated ammonium sulfate at 4°C overnight. The precipitated bacteriocin was centrifuged at 10000 rpm to remove the ammonium sulfate solution, and the precipitate was dried to obtain the bacteriocin.

[0073] Select Listeria monocytogenes ATCC 19111 and inoculate it into sterilized TSA liquid medium, culture it at 37℃ for 14-16 h, and dilute the pathogen to a concentration of 1×10 8 CFU / mL, inoculate 1% in solid TSA medium at 45~55℃, mix well, pour 20 mL / plate on the plain agar plate with Oxford cup, wait for it to cool and solidify, and take out the Oxford cup. Add 150 μL of different concentrations of the sample to be tested (Bacillus coagulans bacteriocin) to the well, let it stand at 4℃ for 2~4h, and then culture it at 37℃ for 24h. The results are as follows Figure 6 shown.

[0074] The Clostridium perfringens CVCC 2027 stored in the cryopreservation tube was inoculated into the sterilized RCM liquid culture medium, the surface was sealed with sterile liquid paraffin, and the culture was kept at 47℃ for 12 h. The bacterial solution was diluted with physiological saline to make the OD 600 To between 0.04 and 0.06, inoculate 1% in solid RCM medium at 45-55°C, mix well, pour 20 mL / plate on the plain agar plate with the Oxford cup, wait for it to cool and solidify, and take out the Oxford cup. Add 150 μL of the sample of different concentrations to the well, put it in an anaerobic bag, add an anaerobic bag and seal it, and culture it at 37°C for 24 h. The results are as followsFigure 7 shown.

[0075] Staphylococcus aureus ATCC 25923 was selected and inoculated into sterilized LB liquid medium. After culturing at 37°C for 12-14 h, it was diluted to 1×10 8 CFU / mL, inoculate 1% in solid LB medium at 45~55℃, mix well, pour 20 mL / plate on the plain agar plate with Oxford cup, wait for it to cool and solidify, and take out the Oxford cup. Add 150 μL of the sample of different concentrations to the well, let it stand at 4℃ for 2~4 hours, and then culture it at 37℃ for 24 hours. The results are as follows Figure 8 shown.

[0076] These results indicate that B. coagulans BCH0 is able to secrete bacteriocins that are specific for Gram-positive pathogens, including Listeria monocytogenes, Clostridium perfringens, and Staphylococcus aureus (Table 2).

[0077] Table 2 Inhibitory effect of Bacillus coagulans BCH0 on pathogenic bacteria

[0078] Example 3 Bacillus coagulans ( Bacillus coagulans )BCH0 sensitivity analysis test to different antibiotics

[0079] Antibiotic sensitivity was determined by drug sensitivity paper. Several common antibiotics were selected as representatives from each category to comprehensively evaluate the drug sensitivity of BCH0. Then 1% of the Bacillus coagulans BCH0 bacterial solution was added to the liquid YPD solid culture medium and mixed until the YPD culture medium solidified and dried for 3-5 minutes. Place the tablet in the center of the plate and press it gently. Place one tablet on each plate. The plates were incubated in a 47°C incubator for 36 hours, and the size of the antibacterial circle was observed. Each tablet was repeated three times. The diameter of the inhibition zone is less than 15 mm for resistance, 16-20 mm for moderate sensitivity, and greater than 20 mm for sensitivity. The test results are as follows: Figure 9 As shown, the analysis after measuring the inhibition diameter showed that Bacillus coagulans BCH0 was sensitive to 28 antibiotics including penicillin, tetracycline and erythromycin (Table 3), indicating that Bacillus coagulans BCH0 was not resistant.

[0080] Table 3 Antibiotic sensitivity table of Bacillus coagulans BCH0

[0081] Example 4 Bacillus coagulans ( Bacillus coagulans ) Safety evaluation of BCH0 in mice

[0082] Twelve 7-8-week-old C57BL / 6 mice with an initial body weight of 20-25 g were randomly divided into two groups: one group was given intragastric administration of normal saline (CON group) and the other group was given 1×10 8 CFU / mL BCH0 28 days, gavage once every two days, gavage volume of 200 μL / mouse, continuous treatment for 14 days. The room temperature was maintained at 25±2 ℃, the relative humidity was maintained at 65%, and the light and dark were alternately illuminated for 12 hours. The weight of the mice was recorded during this period, and the mice were sampled on the 28th day. The heart index, liver index, spleen index and kidney index, the results are shown in Table 4. Bacillus coagulans BCH0 had no obvious side effects on the growth and major organs of mice, and all mice survived at the end of the experiment.

[0083] Table 4 Safety evaluation of feeding Bacillus coagulans BCH0 on the growth of mice

[0084] After the experiment, the mice were killed by dislocating the neck, and the intact mouse heart, liver, spleen, and kidney were removed by dissection. The samples were placed in 4% paraformaldehyde for fixation, and sliced ​​by HE staining to observe the tissue morphology. The tissue morphology results are shown in Figure 10 The results showed that feeding Bacillus coagulans BCH0 had no significant effect on the growth of mice, no obvious damage to major organs, and no safety risk to mice.

[0085] Example 5 Bacillus coagulans ( Bacillus coagulans ) Solid-state fermentation of BCHO

[0086] The solid-state fermentation method of Bacillus coagulans BCHO comprises the following steps: (1) Bacterial strain resuscitation and activation: Bacillus coagulans ( Bacillus coagulans ) BCHO was thawed in the cryotube and inoculated on a solid bromocresol purple broth agar plate. It was cultured at 47°C for 12 h until a single colony grew. The typical characteristics of the colony were yellow colonies with smooth edges. A single colony was picked again and inoculated on a solid bromocresol purple broth agar plate.

[0087] (2) Preparation of primary seed solution: Select a single colony from the seed plate and inoculate it into a YPD liquid shake flask. Incubate it at 47°C and 200 r / min for 12 h as the primary seed solution. 600 Control is 1.8±0.2 is 1.8.

[0088] (3) Preparation of secondary seed solution: Inoculate the primary seed solution at a ratio of 2% into a YPD liquid fermenter, culture at 47°C, control the dissolved oxygen range to 15%, and fill the solution in a volume of 30 L. The fermentation time is controlled to 16 h.

[0089] (4) Solid-state fermentation: The solid-state fermentation material was sterilized at 121°C for 15 min and then cooled for use. The deep fermentation liquid was inoculated into the solid-state fermentation medium at a ratio of 35% and stirred evenly. The stirring and fermentation temperature of the solid-state fermentation were controlled and maintained at 47°C. The fermentation was carried out for 36 h to obtain a solid bacterial agent. The number of live bacteria in the solid product obtained after drying and crushing the solid-state fermentation bacterial agent could reach 7.6×10 8 CFU / g.

[0090] Furthermore, the present invention provides a solid-state fermentation medium formula, whose components, measured by weight, are specifically: 200 parts of bran, 40 parts of soybean meal powder, 20 parts of corn flour, 30 parts of maltodextrin, 10 parts of corn cob powder, 1 part of potassium dihydrogen phosphate and 0.8 parts of manganese sulfate monohydrate.

[0091] Example 6 Bacillus coagulans ( Bacillus coagulans )Analysis of heat resistance and acid resistance of BCH0

[0092] After solid-state fermentation, Bacillus coagulans was further induced to produce spores at 80°C for 10 min to prepare spore samples, and their heat resistance and acid resistance were analyzed.

[0093] In the heat resistance test, the spore samples were placed in 60℃, 70℃, and 80℃ incubators for 10 min and 20 min respectively. The treated samples were mixed thoroughly according to 1 g solid + 9 mL sterile saline. The viable bacteria count test was performed by diluting the suspension in a 10-fold gradient, taking 100 μL of the bacterial solution and applying it to the bromocresol purple solid culture medium. The culture was cultured in a 47℃ incubator for 24 to 36 h, and the plates with colonies between 30 and 300 were selected for colony counts. The untreated samples were used as controls to calculate the survival rate. The test results are as follows: Figure 11 As shown in the data, at 60℃ and 70℃, treatment of solid material for 10-20 min had no significant effect on the number of viable bacteria. After treatment at 80℃ for 20 min, about 84.87% of Bacillus coagulans BCH0 could still be retained.

[0094] In the acid resistance test, the Bacillus sample was placed in YPD liquid culture medium (adjust the pH to 2, 3, 4, 5, and 7 before sterilization, and placed in a conical flask at a ratio of 1 g solid + 9 mL liquid, and cultured at 37°C with shaking for 10 min. The bacterial solution was taken and the viable bacteria were counted as described above. The survival rate was calculated using the YPD solution at pH 7 as the control. The test results are shown in Figure 11 As shown in the figure, as the pH decreased, the survival rate of Bacillus coagulans BCH0 gradually decreased. When pH = 2, the survival rate of Bacillus coagulans BCH0 could still maintain a high level of about 85.2%.

[0095] Example 7 Bacillus coagulans ( Bacillus coagulans)Application of BCH0 in broiler breeding and its regulation of intestinal flora

[0096] 1. Bacillus coagulans ( Bacillus coagulans )Effects of BCH0 on growth performance of AA broilers

[0097] Bacillus coagulans ( Bacillus coagulans )The product prepared by solid-state fermentation of BCH0 was added to the basal diet of broilers at 0.5%. 216 1-day-old AA broilers were selected for the experiment and divided into two treatment groups, with six replicates in each treatment group and 18 chickens in each replicate. The blank control group was fed with the basal diet (Con), and the treatment group was fed with the basal diet + 0.5% of BCH0 solid-state fermentation products. The experiment was divided into the early and late stages, the early stage was 1-21 days, and the late stage was 22-42 days. During the experiment, the temperature and humidity of the chicken house were adjusted every day, and the weight of the broilers was weighed at 1 day, 21 days and 42 days, and the feed intake of the broilers was weighed. After the experiment, the average daily weight gain, average daily feed intake and feed-to-weight ratio were calculated for each replicate. The experimental results showed that adding 0.5% Bacillus coagulans BCH0 to the diet could significantly increase the average daily weight gain of broilers, increase feed intake and improve feed conversion efficiency. The average daily weight gain increased by 11.8%, the average daily feed intake increased by 9.91%, and the feed-to-weight ratio decreased by 2.04% (Table 5).

[0098] Table 5 Effects of feeding Bacillus coagulans BCH0 on the growth performance of AA broilers

[0099] 2. Bacillus coagulans ( Bacillus coagulans )Regulatory effect of BCH0 on intestinal flora of AA broilers

[0100] After the above feeding experiment, the jejunum, ileum and tissue samples of AA broiler chickens were collected and placed in 4% paraformaldehyde for fixation. The slices were made by HE staining to observe the tissue morphology. The tissue morphology results are shown in Figure 12 The results showed that feeding 0.5% Bacillus coagulans had no obvious damage to the small intestine of broiler chickens. The height of intestinal villi was measured using Image J software. The experimental results showed that Bacillus coagulans could significantly increase the height of ileal villi and provide intestinal digestion and absorption function for broiler chickens.

[0101] The ileal chyme of AA broilers was collected for intestinal microbial composition analysis, and the chyme samples were sent to Shanghai Meiji Biomedical Technology Co., Ltd. for microbiome detection and analysis. The ileal chyme samples were analyzed using the 16S rDNA sequencing method. Figure 13As shown, ACE and Chao1 indexes reflect the α diversity of microorganisms. The results showed that the ACE and Chao1 values ​​of the BCH0 group with the addition of Bacillus coagulans were higher than those of the control group. The β diversity was analyzed using NMDS, and the results showed that there was no significant difference between the BCH0 group and the control group.

[0102] From the analysis of microbial genus level, after the addition of Bacillus coagulans BCH0, the ileal flora changed significantly, and the dominant flora was Roseburia. Romboutsia Lactobacillus Lactobacillus In addition, the addition of BCH0 strain reduced the number of Roseburia Romboutsia Zurichobacter Turicibacter , Candida albicans Candidatus_ Arthromitus and Roseburia mucosa Rothia The abundance of probiotic-related Lactobacillus Lactobacillus , Streptococcus Streptococcus , Peptostreptococcus Peptostreptococcaceae , Bacillus Bacillus Eubacterium Blautia The abundance of Figure 14 ).

[0103] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made based on the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.

Claims

1. Bacillus coagulans ( Bacillus coagulans )BCH0, the deposit number is CGMCC No.26478.

2. A bacterial agent containing the Bacillus coagulans according to claim 1.

3. A feed additive or animal feed containing the Bacillus coagulans according to claim 1.

4. A medicine or composition containing the Bacillus coagulans according to claim 1.

5. A bacteriocin produced by the Bacillus coagulans according to claim 1.

6. The method for preparing the bacteriocin according to claim 5, It is characterized in that The method comprises: fermenting and culturing the coagulant Bacillus of claim 1, centrifuging the fermentation liquid to obtain the supernatant, precipitating the supernatant with ammonium sulfate, and centrifuging after precipitation to obtain a crude bacteriocin; Preferably, the fermentation culture uses MRS liquid medium.

7. Use of the Bacillus coagulans according to claim 1, the bacterial agent according to claim 2 or the bacteriocin according to claim 5 in the preparation of antibacterial biological products; The inhibitory targets are Gram-positive pathogens, including Staphylococcus aureus ( Staphylococcus aureus )、Listeria monocytogenes( Listeria monocytogenes ) and Clostridium perfringens ( Clostridium perfringens ).

8. The solid-state fermentation method of Bacillus coagulans according to claim 1, It is characterized in that The following steps are involved: (1) Resuscitation and activation of strains: Bacillus coagulans is thawed in a frozen tube and inoculated onto a solid bromocresol purple broth agar plate and cultured until a single colony grows; (2) Preparation of primary seed solution: Select a single colony from the plate and inoculate it into a YPD liquid shake flask and culture it until OD 600 The range is 1.5~2.0, which is used as the first-level seed solution; (3) Preparation of secondary seed solution: Inoculate the primary seed solution into a YPD liquid fermenter at a volume ratio of 0.5% to 5%, culture at 30 to 50°C, control the dissolved oxygen range to 10% to 30%, and fill the solution at 30 to 100 L; the fermentation time is controlled to be 16 to 24 h; (4) Solid-state fermentation: The solid-state fermentation material was sterilized at 110°C-121°C for 10-20 min and then cooled as a solid-state fermentation medium. The secondary seed liquid was inoculated into the solid-state fermentation medium at a ratio of 10%-50% by mass and stirred evenly. The stirring and fermentation temperature of the solid-state fermentation were controlled and maintained at 30-50°C. The fermentation was carried out for 24-48 h to obtain a solid-state inoculum. After the solid-state fermentation inoculum was dried and crushed, the number of viable bacteria in the solid-state fermentation product reached 5.0×10 8 ~9.0×10 8 CFU / g.

9. The method according to claim 8, It is characterized in that The solid fermentation material comprises, by weight, 100-200 parts of bran, 30-50 parts of soybean meal powder, 10-30 parts of corn flour, 10-30 parts of maltodextrin, 5-10 parts of corn cob powder, 1-2 parts of potassium dihydrogen phosphate and 0.5-1 part of manganese sulfate monohydrate.

10. Use of the Bacillus coagulans according to claim 1 or the solid-state fermentation product prepared according to the method according to claim 8 or 9 as a feed additive for improving the growth performance of livestock and poultry and improving the intestinal flora of animals.

Citation Information

Cited By

  • Bacillus coagulans as well as fermentation culture method and application thereof

    CN120290365A